Testing Tumor Tissue and Blood to Help Select Personalized Treatments for Patients With Suspected Lung Cancers

Summary

This collaborative screening protocol, developed by the Lung Cancer Mutation Consortium (LCMC) and supported by the Thoracic Surgery Oncology Group (TSOG), is designed to determine the feasibility of comprehensive molecular profiling to detect actionable oncogenic drivers in patients with suspected early stage lung cancers scheduled to undergo biopsies to establish the diagnosis of lung cancer.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• NSCLC

Eligibility basics and study details

Study type

Observational

Phase

Not applicable

Ages

Any age

Sex

All

Healthy volunteers

Not accepted

Sponsor

Lung Cancer Mutation Consortium

Last updated on ClinicalTrials.gov

November 12, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites